GLP-3-RT

GLP-3-RT (Retatrutide) is a synthetic multi-receptor agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is studied in preclinical and clinical research as a triagonist compound for investigating multi-incretin pathway modulation and metabolic signaling.

Retatrutide is a synthetic triagonist peptide that simultaneously engages GLP-1, GIP, and glucagon receptors. It is studied in research for multi-incretin pathway modulation and metabolic signaling dynamics. Supplied as a lyophilized research peptide.

Retatrutide was developed as a triple-agonist peptide targeting three key metabolic receptors — GLP-1R, GIPR, and GCGR. It emerged from pharmaceutical research into multi-receptor agonism as an approach to studying the interplay between incretin and glucagon signaling pathways. Its triagonist profile represents an evolution from mono- and dual-agonist research compounds.

Published preclinical and clinical research has characterized Retatrutide's triagonist binding profile across GLP-1, GIP, and glucagon receptors. Studies have examined its effects on metabolic signaling parameters, including glucose homeostasis, energy expenditure markers, and lipid metabolism in various research models. Its unique triple-receptor engagement differentiates it from single- and dual-agonist compounds in pharmacological research.